Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Licitra

Showing results (261-270 of 311) with videos related to

Pageof 32
Sort By:
Cells|October 14, 2022
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck CancerStefano Cavalieri, Mara Serena Serafini, Andrea Carenzo, et al.
Frontiers in Oncology|October 2, 2023
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructureLaura Botta, Tomohiro Matsuda, Hadrien Charvat, et al.
Plos One|July 30, 2020
Correction: Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapySimon Keek, Sebastian Sanduleanu, Frederik Wesseling, et al.
Critical Reviews in Oncology/Hematology|July 5, 2015
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensusAntonio Schindler, Nerina Denaro, Elvio G Russi, et al.
Plos One|May 23, 2020
Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapySimon Keek, Sebastian Sanduleanu, Frederik Wesseling, et al.
Journal for Immunotherapy of Cancer|September 8, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancerCaroline Even, Kevin J Harrington, Erminia Massarelli, et al.
Frontiers in Oncology|February 17, 2023
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocolStefano Cavalieri, Claudia Vener, Marissa LeBlanc, et al.
Future Oncology (London, England)|June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 StudyLisa Licitra, Makoto Tahara, Kevin Harrington, et al.
Journal for Immunotherapy of Cancer|July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
Pageof 32

Showing results (261-270 of 311) with videos related to

Sort By:
Pageof 32
Cells|October 14, 2022
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck CancerStefano Cavalieri, Mara Serena Serafini, Andrea Carenzo, et al.
Frontiers in Oncology|October 2, 2023
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructureLaura Botta, Tomohiro Matsuda, Hadrien Charvat, et al.
Plos One|July 30, 2020
Correction: Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapySimon Keek, Sebastian Sanduleanu, Frederik Wesseling, et al.
Critical Reviews in Oncology/Hematology|July 5, 2015
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensusAntonio Schindler, Nerina Denaro, Elvio G Russi, et al.
Plos One|May 23, 2020
Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapySimon Keek, Sebastian Sanduleanu, Frederik Wesseling, et al.
Journal for Immunotherapy of Cancer|September 8, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancerCaroline Even, Kevin J Harrington, Erminia Massarelli, et al.
Frontiers in Oncology|February 17, 2023
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocolStefano Cavalieri, Claudia Vener, Marissa LeBlanc, et al.
Future Oncology (London, England)|June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 StudyLisa Licitra, Makoto Tahara, Kevin Harrington, et al.
Journal for Immunotherapy of Cancer|July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
Pageof 32